Dr. Don C. Rockey, MD
Hepatology (Hepatology Physician)
- Medicare participating
At a glance
- Years since graduation
- 42
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 65
Licensed in Texas since 2006, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hepatology Physician primary
SC license 35532 -
Gastroenterology Physician
SC license 35532 · TX license M3372 (first issued 2006; cancelled by request)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Musc Medical Center Charleston, SC
Medical groups
- University Medical Associates of the Medical University of South Carol (1,668 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 65
- Services billed
- 201
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 32 | 18 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 26 | 26 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 13 | 12 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 2 companies reported 14 payments worth $13,387 in total to this clinician.
| Intercept Pharmaceuticals, Inc. | $13,353 |
|---|---|
| Novo Nordisk Inc | $34.07 |
| Consulting Fee | $11,559 |
|---|---|
| Travel and Lodging | $1,554 |
| Food and Beverage | $275 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Intercept Pharmaceuticals, Inc. Mar 29, 2025 | Consulting Fee OCALIVA · Hepatology / Gastroenterology | $3,850 |
| Intercept Pharmaceuticals, Inc. Jun 13, 2025 | Consulting Fee OCALIVA · Hepatology / Gastroenterology | $2,094 |
| Intercept Pharmaceuticals, Inc. Jun 13, 2025 | Consulting Fee OCALIVA · Hepatology / Gastroenterology | $2,094 |
| Intercept Pharmaceuticals, Inc. Mar 3, 2025 | Consulting Fee OCALIVA · Hepatology / Gastroenterology | $1,760 |
| Intercept Pharmaceuticals, Inc. Mar 3, 2025 | Consulting Fee OCALIVA · Hepatology / Gastroenterology | $1,760 |
| Intercept Pharmaceuticals, Inc. Mar 29, 2025 | Travel and Lodging OCALIVA · Hepatology / Gastroenterology · travel to Chicago, IL | $843 |
| Intercept Pharmaceuticals, Inc. Mar 28, 2025 | Travel and Lodging OCALIVA · Hepatology / Gastroenterology · travel to Chicago, IL · in-kind | $257 |
| Intercept Pharmaceuticals, Inc. Mar 29, 2025 | Travel and Lodging OCALIVA · Hepatology / Gastroenterology · travel to Chicago, IL · in-kind | $250 |
| Intercept Pharmaceuticals, Inc. Mar 28, 2025 | Travel and Lodging OCALIVA · Hepatology / Gastroenterology · travel to Chicago, IL · in-kind | $204 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 7 companies. The companies reported $455,952 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Madrigal Pharmaceuticals · Active, not recruiting · NCT04951219 - A Two Part Phase IIa b Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-ranging Study to Assess Efficacy, Safety, and Tolerability of the Combination of Zibotentan and Dapagliflozin, and …
AstraZeneca Pharmaceuticals LP - A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alco…
Intercept Pharmaceuticals, Inc. - A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis
Bausch Health US, LLC - Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
Ipsen Bioscience Inc. · Active, not recruiting · NCT04526665 - A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
Ipsen Pharma Sas · Active, not recruiting · NCT06447168 - A Multicentre Randomised Double-blind Placebo-Controlled Phase 2b Study to Evaluate the Safety of ZibotentanDapagliflozin in Combination Compared to Zibotentan Monotherapy as well as ZibotentanDapagliflozin and Zibote…
AstraZeneca Pharmaceuticals LP - A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
Ipsen Bioscience Inc. · Active, not recruiting · NCT05627362 - Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presume…
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.